SIS Shulov Innovative Science

Company Overview

Snapshot

Founded in January 1985 by Aviv Marx and Ophir Shahaf, SIS Shulov Innovative Science operates with 11–50 employees. The company is currently in the Pre-Funding stage, focusing on developing New Chemical Entities for various therapeutic uses. A significant milestone includes the completion of a Phase II clinical study in Herpes Labialis.

Business overview

SIS Shulov Innovative Science is a clinical-stage biopharmaceutical company developing New Chemical Entities (NCEs) for diverse therapeutic applications, particularly in dermatology. The company's core technology involves short synthetic peptides, branded as ZEP-3 and ZEP-4, which exhibit combined anti-inflammatory, anti-viral, and analgesic properties. SIS serves the pharmaceutical and healthcare markets, with a focus on addressing conditions such as Herpes Labialis and Atopic Dermatitis in the United States and Israel.

Company Intelligence Q&A

What is SIS Shulov Innovative Science's primary focus?

SIS Shulov Innovative Science focuses on developing New Chemical Entities (NCEs) for various therapeutic uses, with a particular emphasis on dermatology.

What are the key products or technologies developed by SIS Shulov Innovative Science?

The company's key products are short synthetic peptides branded as ZEP-3 and ZEP-4, which possess unique biological activity as anti-inflammatory, anti-viral, and analgesic agents.

What clinical trials has SIS Shulov Innovative Science completed or is currently conducting?

SIS Shulov Innovative Science completed a Phase II clinical study in Herpes Labialis and is conducting a Phase II clinical study in Atopic Dermatitis across nine clinical sites in Israel.

Which markets does SIS Shulov Innovative Science target?

SIS Shulov Innovative Science targets the United States and Israel for its pharmaceutical developments.

What is the current development stage of SIS Shulov Innovative Science's products?

The company's products are currently in the clinical trial stage, with preparations for an advanced Phase III clinical trial in Herpes Labialis patients in the US and ongoing Phase II studies for Atopic Dermatitis.